Rethinking Diagnostics Contracts

The nation's largest GPOs are rethinking the way they contract with diagnostics industry suppliers in light of new workstation consolidation coming on the market. Novation is considering combining immunoassay and clinical chemistry onto one contract; Premier is planning to hold a conference for members on the future of diagnostics and then a meeting of its laboratory task force to think of how to use new technologies.

One sign that workstation consolidation is becoming a reality in the clinical laboratory: two of the nation's largest group purchasing organizations (GPOs) say they are rethinking the way they contract for certain laboratory segments, notably clinical chemistry and immunoassay. Novation Inc., the year-old GPO formed from the merger of VHA Inc. and University HealthSystem Consortium, is considering in the future combining its now separate contracts for clinical chemistry and immunoassay equipment, not only because of technological innovations, but also because of the overwhelming need to drive efficiencies for laboratory operations.

And Premier Inc. is also reconsidering its approach to diagnostics. To this end, it is planning for the first...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Innovation

Finding The Fire: AltruBio’s Novel Approach To Autoimmune Disease

 
• By 

CEO Judy Chou brings big pharma experience to tackle chronic inflammation with the company's first-in-class PSGL-1 targeting therapy.

Late-Stage GLP-1 Drug Trials Outside The Cardiometabolic Space

 
• By 

A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.

AI In Health Delivery: Patients Most Confident When HCPs Are In Charge

 
• By 

Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.

Medtech Innovators Court London-Based Investors At BioWales 2025

 
• By 

BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.

More from In Vivo

AI In Health Delivery: Patients Most Confident When HCPs Are In Charge

 
• By 

Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.

Medtech Innovators Court London-Based Investors At BioWales 2025

 
• By 

BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By 

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.